Share-based Payment Arrangement, Expense of Protagonist Therapeutics, Inc from 31 Dec 2014 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Protagonist Therapeutics, Inc quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2014 to 30 Sep 2025.
  • Protagonist Therapeutics, Inc Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $10,559,000, a 3.9% increase year-over-year.
  • Protagonist Therapeutics, Inc Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $44,366,000, a 27% increase year-over-year.
  • Protagonist Therapeutics, Inc annual Share-based Payment Arrangement, Expense for 2024 was $37,554,000, a 28% increase from 2023.
  • Protagonist Therapeutics, Inc annual Share-based Payment Arrangement, Expense for 2023 was $29,293,000, a 21% increase from 2022.
  • Protagonist Therapeutics, Inc annual Share-based Payment Arrangement, Expense for 2022 was $24,202,000, a 48% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Protagonist Therapeutics, Inc Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $44,366,000 $10,559,000 +$394,000 +3.9% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $43,972,000 $10,912,000 +$1,968,000 +22% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $42,004,000 $13,802,000 +$4,450,000 +48% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $37,554,000 $9,093,000 +$2,492,000 +38% 01 Oct 2024 31 Dec 2024 10-K 21 Feb 2025 2024 FY
Q3 2024 $35,062,000 $10,165,000 +$3,400,000 +50% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $31,662,000 $8,944,000 +$601,000 +7.2% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $31,061,000 $9,352,000 +$1,768,000 +23% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $29,293,000 $6,601,000 +$1,089,000 +20% 01 Oct 2023 31 Dec 2023 10-K 21 Feb 2025 2024 FY
Q3 2023 $28,204,000 $6,765,000 +$815,000 +14% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $27,389,000 $8,343,000 +$1,538,000 +23% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $25,851,000 $7,584,000 +$1,649,000 +28% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $24,202,000 $5,512,000 +$488,000 +9.7% 01 Oct 2022 31 Dec 2022 10-K 21 Feb 2025 2024 FY
Q3 2022 $23,714,000 $5,950,000 +$1,175,000 +25% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $22,539,000 $6,805,000 +$2,869,000 +73% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $19,670,000 $5,935,000 +$3,275,000 +123% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $16,395,000 $5,024,000 +$3,057,000 +155% 01 Oct 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
Q3 2021 $13,338,000 $4,775,000 +$2,887,000 +153% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $10,451,000 $3,936,000 +$1,940,000 +97% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $8,511,000 $2,660,000 +$612,000 +30% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $7,899,000 $1,967,000 -$193,000 -8.9% 01 Oct 2020 31 Dec 2020 10-K 15 Mar 2023 2022 FY
Q3 2020 $8,092,000 $1,888,000 -$313,000 -14% 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021 2021 Q3
Q2 2020 $8,405,000 $1,996,000 -$17,000 -0.84% 01 Apr 2020 30 Jun 2020 10-Q 04 Aug 2021 2021 Q2
Q1 2020 $8,422,000 $2,048,000 +$69,000 +3.5% 01 Jan 2020 31 Mar 2020 10-Q 04 May 2021 2021 Q1
Q4 2019 $8,353,000 $2,160,000 +$88,000 +4.2% 01 Oct 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
Q3 2019 $8,265,000 $2,201,000 +$184,000 +9.1% 01 Jul 2019 30 Sep 2019 10-Q 04 Nov 2020 2020 Q3
Q2 2019 $8,081,000 $2,013,000 +$368,000 +22% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $7,713,000 $1,979,000 +$794,000 +67% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $6,919,000 $2,072,000 +$882,000 +74% 01 Oct 2018 31 Dec 2018 10-K 10 Mar 2021 2020 FY
Q3 2018 $6,037,000 $2,017,000 +$810,000 +67% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019 2019 Q3
Q2 2018 $5,227,000 $1,645,000 +$644,000 +64% 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019 2019 Q2
Q1 2018 $4,583,000 $1,185,000 +$342,000 +41% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q4 2017 $4,241,000 $1,190,000 -$330,000 -22% 01 Oct 2017 31 Dec 2017 10-K 10 Mar 2020 2019 FY
Q3 2017 $4,571,000 $1,207,000 +$759,000 +169% 01 Jul 2017 30 Sep 2017 10-Q 06 Nov 2018 2018 Q3
Q2 2017 $3,812,000 $1,001,000 +$895,000 +844% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018 2018 Q2
Q1 2017 $2,917,000 $843,000 +$787,000 +1405% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
Q4 2016 $2,130,000 $1,520,000 01 Oct 2016 31 Dec 2016 10-K 12 Mar 2019 2018 FY
Q3 2016 $448,000 +$426,000 +1936% 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3
Q2 2016 $106,000 +$85,000 +405% 01 Apr 2016 30 Jun 2016 10-Q 08 Aug 2017 2017 Q2
Q1 2016 $56,000 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017 2017 Q1
Q3 2015 $22,000 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016 2016 Q3
Q2 2015 $21,000 01 Apr 2015 30 Jun 2015 10-Q 15 Sep 2016 2016 Q2

Protagonist Therapeutics, Inc Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $37,554,000 +$8,261,000 +28% 01 Jan 2024 31 Dec 2024 10-K 21 Feb 2025 2024 FY
2023 $29,293,000 +$5,091,000 +21% 01 Jan 2023 31 Dec 2023 10-K 21 Feb 2025 2024 FY
2022 $24,202,000 +$7,807,000 +48% 01 Jan 2022 31 Dec 2022 10-K 21 Feb 2025 2024 FY
2021 $16,395,000 +$8,496,000 +108% 01 Jan 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
2020 $7,899,000 -$454,000 -5.4% 01 Jan 2020 31 Dec 2020 10-K 15 Mar 2023 2022 FY
2019 $8,353,000 +$1,434,000 +21% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 $6,919,000 +$2,678,000 +63% 01 Jan 2018 31 Dec 2018 10-K 10 Mar 2021 2020 FY
2017 $4,241,000 +$2,111,000 +99% 01 Jan 2017 31 Dec 2017 10-K 10 Mar 2020 2019 FY
2016 $2,130,000 +$2,031,000 +2052% 01 Jan 2016 31 Dec 2016 10-K 12 Mar 2019 2018 FY
2015 $99,000 +$57,000 +136% 01 Jan 2015 31 Dec 2015 10-K 07 Mar 2018 2017 FY
2014 $42,000 01 Jan 2014 31 Dec 2014 10-K 07 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.